Regeneron’s Gift: New Hope Against Devastating Ebola Risk
Regeneron will donate up to 500 doses of Inmazeb, its FDA‑approved monoclonal antibody cocktail for infection caused by Orthoebolavirus...
eClinical Tech News
Promising New Olanzapine LAI Data Reveals No Observed PDSS
Teva spotlighted its schizophrenia portfolio at Psych Congress 2025, unveiling long-term Phase 3 data for its investigational once-monthly olanzapine...
Iovance Biotherapeutics Reports New Nasdaq Inducement Grants
Iovance Biotherapeutics has granted inducement stock options covering 22,810 shares to two new non-executive hires, with an exercise price...
Breakthrough Carbon Capture Tech is Scalable and Modular
Decarbontek has launched a modular, fiber-based adsorbent platform intended to scale point-source carbon capture and direct air capture by...
New Data on Semaglutide’s Food Noise, CV Benefits at EASD
Novo Nordisk will bring 35 presentations to EASD 2025 in Vienna, spanning late- and early-stage evidence across its semaglutide...
New Phase 1 Study Results for NBTXR3 in Resistant Melanoma
Nanobiotix reported new Phase 1 data in primary cutaneous melanoma showing that a one-time intratumoral injection of JNJ-1900 (NBTXR3),...
Rezolute Reports Q4 & Full Year Fiscal 2025 Financials
Rezolute reported fiscal 2025 results alongside two pivotal clinical inflection points for its lead asset, ersodetug: completion of enrollment...
Successful Accreditation for Plus Therapeutics’ CNSide Lab
CNSide Diagnostics, a wholly owned subsidiary of Plus Therapeutics, has received a CMS certificate of accreditation under CLIA for...
Epitopea Adds Four Immunology Experts to Scientific Board
Epitopea has expanded its scientific advisory board with four high-profile appointments—Nahum Sonenberg, Nina Bhardwaj, Margaret Callahan, and Craig L....
Roche’s New Merger with 89bio Targets Promising MASH Therapy
Roche has signed a definitive agreement to acquire 89bio for $14.50 per share in cash, plus a non-tradeable contingent...